| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Evogene Ltd.$0.5
+0.09 (+20.74%)
D 26Pipeline Score Overvalued Biotech · Clinical
Market Cap
7.14 M
EPS
-1.38
P/E Ratio
-0.43 $
Value Trade
525.53 K
-3.18 %
Week
-11.39 %
1 Month
-20.34 %
3 Month
-36.36 %
6 Month
-98.13 %
5 Year
-94.81 %
All Time
Cash Data
Cash Position
12.35 K
Monthly Burn
12.35 K
Runway
12,345 mo
Overview
Volume
33.16 M
52 Week Range
0.52 - 2.42
% held by Insiders
0.69 %
% held by Institutions
4.97 %
Enterprise Value
6.62 M
Total Shares
8.72 M
Short %
3.63 %
Float Shares
8.63 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
D26
Pipeline Score $3M
Pipeline ValueOvervalued
Valuation Signal1
Drugs Scored0.4x
rNPV / MCap Top 26%
Micro Cap (rank 671 of 906)
Percentile RankEvogene Ltd. faces pipeline headwinds (26/100), with $408M risk-adjusted pipeline value, led by BMC128 in Non-small Cell Lung Cancer (Phase 1).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BMC128 Small molecule | Non-small Cell Lung Cancer | Phase 1 | NCT05354102 | 10% | $408M | ACTIVE NOT_RECRUITING | 11 | STALLED | D (31) | Nov 1, 2025 | - | LOW May 26, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
BMC128 | advanced solid tumors | Phase 1 | 2026-06-02 | total patients: 11; stable disease patients: 5; partial response patients: 1; patients on study: 2 Read More | Evogene Announces Successful Completion of Phase 1 Clinical Study of BMC128, a Rationally Designed Live Bacterial Product, in Combination with Nivolumab by its Subsidiary Biomica Read More | |
BMC128 | advanced solid tumors | Phase 1 | 2026-06-02 | total patients: 11; stable disease patients: 5; partial response patients: 1; patients on study: 2 Read More | Evogene Announces Successful Completion of Phase 1 Clinical Study of BMC128, a Rationally Designed Live Bacterial Product, in Combination with Nivolumab by its Subsidiary Biomica Read More | |
BMC128 | advanced solid tumors | Phase 1 | 2026-06-02 | total patients: 11; stable disease patients: 5; partial response patients: 1; patients on study: 2 Read More | Evogene Announces Successful Completion of Phase 1 Clinical Study of BMC128, a Rationally Designed Live Bacterial Product, in Combination with Nivolumab by its Subsidiary Biomica Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in EVGN
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
EVGN Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
EVGNEvogene to Present Its Pharma Division Achievements at the BIO International Convention
Conference to be held in San Diego, CA, USA – June 22-25, 2026 REHOVOT, Israel, June 9, 2026 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a pioneering company in computational chemistry specializing in AI-based generative design of small molecules for the pharmaceut
Read more →EVGN▼ -13.6%on this news
Evogene Announces Successful Completion of Phase 1 Clinical Study of BMC128, a Rationally Designed Live Bacterial Product, in Combination with Nivolumab by its Subsidiary Biomica
Evogene Ltd. announced the successful completion of a Phase 1 clinical study of BMC128, a live bacterial product, in combination with Nivolumab for patients with advanced solid tumors. The study demonstrated a favorable safety profile and preliminary signs of clinical activity, with several patients achieving stable disease. The findings support the continued development of BMC128 by Lishan Biotech.
Read more →EVGNEvogene Reports First Quarter 2026 Financial Results
Conference call and webcast: today, May 20, 2026, 9:00 AM ET REHOVOT, Israel, May 20, 2026 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a pioneering company in computational chemistry specializing in the generative AI design of small molecules for the pharmaceutical
Read more →EVGNEvogene to Present at the 24th Schrödinger European User Group Meeting
Conference will be held in Munich, Germany - May 19-21, 2026 REHOVOT, Israel, May 12, 2026 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a pioneering company in computational chemistry specializing in the generative AI design of small molecules for the pharmaceutical
Read more →EVGNEvogene Schedules First Quarter 2026 Financial Results Release
Zoom conference call scheduled for May 20, 2026, 9:00 AM ET REHOVOT, Israel, May 7, 2026 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a pioneering company in computational chemistry, specializing in the generative design of small molecules for the pharmaceutical and
Read more →EVGNEvogene Reports Receipt of Nasdaq Minimum Bid Price Notification
Evogene Ltd. received a notification from Nasdaq regarding non-compliance with the minimum bid price rule, as its shares have been below $1.00 for 30 consecutive business days. The company has 180 days to regain compliance, with options including a potential reverse stock split. Failure to comply may result in delisting from Nasdaq, although trading will continue during this period.
Read more →EVGNEvogene to Present Its Pharma Discovery Achievements at BIO-Europe Spring 2026
Evogene Ltd. will present its latest pharmaceutical discoveries at the BIO-Europe Spring 2026 conference in Lisbon. Key presentations will focus on the company's advancements in AI-driven small-molecule discovery, particularly through its ChemPass AI™ technology. Attendees will have the opportunity to meet with Evogene's executives for further discussions on collaborative drug discovery.
Read more →EVGN▼ -6.2%on this newsshared move
Evogene Reports Fourth Quarter and Full Year 2025 Financial Results
Evogene Ltd. reported its financial results for Q4 and full year 2025, revealing a strategic shift towards its ChemPass AI™ technology for small-molecule discovery in pharma and agriculture. Despite a decrease in revenues and increased operating losses, the company is optimistic about its future, bolstered by advancements in AI and strategic partnerships. The focus on core activities aims to drive sustainable long-term value.
Read more →EVGNEvogene Releases CEO Letter to Shareholders
Evogene Ltd. has issued a letter from CEO Ofer Haviv detailing the company's strategic transformation in 2025, focusing on its ChemPass AI™ platform for drug discovery and agricultural applications. The company has streamlined operations, divested non-core assets, and established strategic partnerships to enhance its market position. Evogene aims to create sustainable value through innovation in human health and agriculture.
Read more →EVGN▼ -5.6%on this news
Evogene Schedules Fourth Quarter and Full Year 2025 Financial Results Release
Zoom conference call scheduled for March 5, 2026, 9:00 AM ET REHOVOT, Israel, Feb. 19, 2026 /PRNewswire/ -- Evogene Ltd . (NASDAQ: EVGN) (TASE: EVGN), a pioneering company in computational chemistry, specializing in the generative design of small molecules for the pharmaceutical
Read more →EVGNEvogene and Queensland University of Technology (QUT) Announce a Collaboration to Advance AI-Driven Cancer Therapeutics
Aiming to introduce a new therapeutic strategy for overcoming chemotherapy resistance in lung cancer due to increased expression of cellular pathways REHOVOT, Israel, Feb. 17, 2026 /PRNewswire/ -- Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a pioneering computational chemistry com
Read more →EVGN▼ -10.2%on this news
Evogene Announces a Warrant Inducement Transaction for Approximately $3.4 Million of Gross Proceeds
Evogene Ltd. has announced a warrant inducement transaction that will generate approximately $3.4 million in gross proceeds. The company will use the funds for working capital and corporate purposes. The agreement involves the immediate exercise of existing warrants at a reduced price, along with the issuance of new warrants to the investor. The transaction is expected to close on February 11, 2026, pending customary conditions.
Read more →EVGN▼ -7.3%on this newsshared move
Evogene Announces Expanded Collaboration with Google Cloud to Integrate AI Agents into ChemPass AI™
Evogene Ltd. has announced an expanded collaboration with Google Cloud to integrate advanced AI agents into its ChemPass AI™ platform. This initiative aims to enhance the efficiency and precision of small-molecule discovery and optimization for pharmaceuticals and agricultural products. The collaboration builds on a previous successful phase and positions Evogene as a leader in next-generation molecular design.
Read more →EVGNEvogene Appoints Prof. John Irwin and Prof. Dan Major to its Scientific Advisory Board
Evogene Ltd. has appointed Prof. John Irwin and Prof. Dan Major to its Scientific Advisory Board to enhance its ChemPass AI™ platform. These experts will provide strategic guidance to improve the discovery and optimization of small molecules for drug development and agricultural chemicals. Their appointments are expected to strengthen Evogene's scientific leadership and innovation in computational chemistry.
Read more →EVGNEvogene and Shanghai Lishan Biopharmaceuticals Co. Announce Exclusive Licensing Agreement for BMC128, a Microbiome-Based Therapeutic for Renal and Lung Cancer
REHOVOT, Israel and SHANGHAI, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Evogene Ltd. (Nasdaq/TASE: EVGN) ("Evogene"), a pioneering computational chemistry company specializing in generative design of small molecules for the pharmaceutical and agricultural industries, and Shanghai Lishan
Read more →EVGNEvogene and Unravel Biosciences Announce Collaboration to Develop a First-in-Class Therapy to Reverse Neurological Damage in Demyelinating Disorders
Evogene Ltd. has partnered with Unravel Biosciences to develop a first-in-class therapy aimed at reversing neurological damage in demyelinating disorders such as Multiple Sclerosis. This collaboration leverages advanced AI technologies and generative chemistry to discover and optimize small-molecule therapeutics. The initiative seeks to address the significant unmet clinical need for effective remyelination therapies.
Read more →EVGNEvogene Announces Appointment of Dr. Olga Nissan as its Vice President of Business Development
Evogene Ltd. has appointed Dr. Olga Nissan as Vice President of Business Development, effective January 1, 2026. Dr. Nissan brings over 15 years of experience in biotechnology and pharmaceuticals, aiming to strengthen Evogene's strategic partnerships and innovative programs. Her expertise aligns with the company's focus on AI-driven drug discovery and development.
Read more →EVGN▼ -7.7%on this news
Evogene Reports Third Quarter 2025 Financial Results
Evogene Ltd. reported its financial results for Q3 2025, highlighting a strategic shift towards AI-driven small molecule discovery through its ChemPass AI platform. The company has streamlined operations and integrated its ag-chemical subsidiary, AgPlenus, into its core business. Despite a decrease in revenue and ongoing operating losses, Evogene aims to capitalize on significant market opportunities.
Read more →EVGNEvogene Schedules Third Quarter 2025 Financial Results Release
Evogene Ltd. has announced the release date for its third quarter 2025 financial results, scheduled for November 20, 2025. The company will host a conference call at 9:00 AM ET to discuss these results. Evogene specializes in computational chemistry and the generative design of small molecules for pharmaceutical and agricultural applications.
Read more →EVGNEvogene to Present at H.C. Wainwright 27th Annual Global Investment Conference in New York
Evogene Ltd. announced that its President and CEO, Ofer Haviv, will present at the H.C. Wainwright 27th Annual Global Investment Conference in New York from September 8-10, 2025. The presentation will focus on the company's ChemPass AI technology for small molecule discovery in pharmaceuticals and agriculture. Mr. Haviv will also be available for one-on-one meetings with interested investors.
Read more →EVGNEvogene Reports Second Quarter 2025 Financial Results
Conference call and webcast: today, August 19, 2025, 9:00 am ET Financial Highlights: The financial results for the first half of 2025 of Lavie Bio, a subsidiary of Evogene and the MicroBoost AI for Ag operations, are presented as a single-line item in Evogene's consolidated st
Read more →EVGNEvogene Schedules Second Quarter 2025 Financial Results Release
Zoom conference call scheduled for August 19, 2025, 9:00 AM ET REHOVOT, Israel, July 29, 2025 /PRNewswire/ -- Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a leading computational biology company targeting to revolutionize life-science product discovery and development, announced to
Read more →EVGN▲ +6.8%on this news
Evogene Announces Completion of Transaction for the Sale of Lavie Bio's Activity to ICL
Evogene Ltd. has successfully completed the sale of its subsidiary Lavie Bio to ICL Group. This transaction includes Lavie Bio's proprietary technology and personnel, aimed at advancing agricultural solutions. The deal aligns with Evogene's strategy to unlock value from its subsidiaries, while Lavie Bio retains its existing partnerships for future revenue opportunities.
Read more →EVGN▲ +100%on this news
Evogene Announces Completion of First-In-Class Foundation Model for Generative Molecule Design, Developed in Collaboration with Google Cloud
Evogene Ltd. has announced the completion of its generative AI foundation model for small molecule design, developed in collaboration with Google Cloud. This model significantly improves the identification of novel small molecules that meet complex criteria, achieving approximately 90% precision compared to traditional methods. The company is also working on version 2.0, which will enhance flexibility for multi-parameter optimization in drug discovery and agricultural applications.
Read more →EVGN▼ -6.7%on this news
Evogene Reports First Quarter 2025 Financial Results
Evogene Ltd. reported its financial results for Q1 2025, highlighting a strategic focus on enhancing its ChemPass-AI tech engine for drug discovery. The company aims to generate cash flow from its subsidiaries while managing a decrease in revenue and cash position. Despite a stable operating loss, Evogene's net loss improved compared to the previous year, reflecting efforts to streamline operations and reduce expenses.
Read more →EVGNEvogene Schedules First Quarter 2025 Financial Results Release
Zoom conference call scheduled for May 21, 2025, 9:00 AM ET REHOVOT, Israel, May 8, 2025 /PRNewswire/ -- May 8, 2025 - Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a leading computational biology company targeting to revolutionize life-science product discovery and development, ann
Read more →EVGNEvogene Announces the Appointment of Nir Nimrodi as the New Chairperson of the Board, Effective March 5, 2025
Mr. Nir Nirmodi is Replacing Ms. Sarit Firon, who will Continue Serving as a Member of the Board REHOVOT, Israel, March 6, 2025 /PRNewswire/ -- Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a leading computational biology company aiming to revolutionize life-science-based product di
Read more →EVGNEvogene Reports Fourth Quarter and Full Year 2024 Financial Results
Conference call and webcast: today, March 6, 2025, 9:00 am ET Financial Highlights: In the year 2024, total revenues reached approximately $8.5 million compared to approximately $5.6 million in the year 2023. The increase in revenues is mainly due to increase in AgPlenus' reven
Read more →EVGN▼ -5.6%on this news
Evogene Schedules Fourth Quarter 2024 Financial Results Release
Zoom conference call scheduled for March 6, 2025, 9:00 AM ET REHOVOT, Israel, Feb. 20, 2025 /PRNewswire/ -- Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a leading computational biology company targeting to revolutionize life-science product discovery and development, announced toda
Read more →EVGNEvogene Reports Third Quarter 2024 Financial Results
Conference call and webcast: today, November 21, 2024, 9:00 am ET Financial Highlights: In the first nine months of 2024, total revenues reached approximately $6.9 million, compared to approximately $5.1 million in the first nine months of 2023. In Q3 2024, total revenues reac
Read more →EVGN▼ -6.7%on this news
Evogene Schedules Third Quarter 2024 Financial Results Release
Zoom conference call scheduled for November 21, 2024, 9:00 AM ET REHOVOT, Israel, Nov. 7, 2024 /PRNewswire/ -- Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a leading computational biology company targeting to revolutionize life-science product discovery and development, announced t
Read more →EVGN▼ -5%on this news· ran to -18% by day 3
Evogene Announces Collaboration with Google Cloud to Pioneer Generative AI Foundation Model for Novel Small Molecule Design
The collaboration has the power to foster breakthroughs in small molecule innovation for life science-based products REHOVOT, Israel, Oct. 31, 2024 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a leading computational biology company aiming to revolutionize life-scie
Read more →EVGNWatershed AC, Evogene and Ben-Gurion University Receive Approval for Second Year Grant to Continue the Collaboration Focused on Improving Crustacean Traits Utilizing Gene Editing Technology
Following a successful first year, Israel Innovation Authority (IIA) approved financing second year of collaboration HAZEVA and REHOVOT, Israel, Oct. 8, 2024 /PRNewswire/ -- Watershed AC ("Watershed", formerly Colors Farm Ltd.), a cutting-edge company in sustainable aquaculture
Read more →EVGN▲ +9.3%on this news
Evogene Announces Pricing of US$5.5 Million Registered Direct Offering and Concurrent Private Placement
REHOVOT, Israel, Aug. 23, 2024 /PRNewswire/ -- Evogene Ltd. ("Evogene" or the "Company") (Nasdaq: EVGN, TASE: EVGN), a leading computational biology company aiming to revolutionize life-science-based product discovery and development utilizing cutting-edge computational biology t
Read more →EVGN▼ -10.8%on this newsshared move
Evogene Reports Second Quarter 2024 Financial Results
Conference call and webcast: today, August 22, 2024, 9:00 am ET Financial and Business Highlights: H1 2024 revenues $5.1M, up from $1.3M in H1 2023; Q2 2024 revenues $914K, up from $654K in Q2 2023. Anticipated continued revenue growth in the second half of 2024 compared to th
Read more →EVGN▼ -6.7%on this news
Evogene Regains Compliance with Nasdaq Minimum Closing Bid Price Rule
REHOVOT, Israel, Aug. 12, 2024 /PRNewswire/ -- Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN) (the "Company", "Evogene"), a leading computational biology company targeting to revolutionize life-science product discovery and development across multiple market segments, today reported th
Read more →EVGN▼ -6.7%on this news
Evogene Schedules Second Quarter 2024 Financial Results Release
Zoom conference call scheduled for 9:00 AM ET REHOVOT, Israel, Aug. 12, 2024 /PRNewswire/ -- Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a leading computational biology company targeting to revolutionize life-science product discovery and development, announced today that it will
Read more →EVGN▼ -14.6%on this news
Evogene Announces Expected Implementation of 1-for-10 Reverse Share Split
Following the reverse share split, the Company will have approximately 5,079,000 Ordinary Shares issued and REHOVOT, Israel, July 23, 2024 /PRNewswire/ -- Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN) (the "Company" or "Evogene"), a leading computational biology company targeting to
Read more →EVGNEvogene Reports First Quarter 2024 Financial Results
Conference call and webcast: today, May 23, 2024, 9:00 am ET Financial and Business Highlights: Q1 2024 revenue: $4.2M vs. $0.6M in Q1 2023; anticipating continued growth in 2024. Q1 2024 net loss: $3.8M vs. $7.0M in Q1 2023. Projected 2024 cash usage, excluding Lavie Bio and
Read more →EVGNEvogene Schedules First Quarter 2024 Financial Results Release
Zoom conference call scheduled for 9:00 AM ET REHOVOT, Israel, May 9, 2024 /PRNewswire/ -- Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a leading computational biology company targeting to revolutionize life-science product discovery and development, announced today that it will re
Read more →EVGNEvogene and The Kitchen FoodTech Hub by Strauss Group Established Finally Foods Ltd. - Revolutionizing Protein Production in Plants for the Food Industry
Finally Foods is financed by the Israeli Innovation Authority (IIA) and The Kitchen Hub, and will be granted a license to utilize Evogene's AI technology REHOVOT, Israel, April 2, 2024 /PRNewswire/ -- Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a leading computational biology comp
Read more →EVGNEvogene Announces Filing of Annual Report on Form 20-F
REHOVOT, Israel, March 28, 2024 /PRNewswire/ -- Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a leading computational biology company targeting to revolutionize life-science-based product discovery and development utilizing cutting edge computational biology technologies, across mult
Read more →EVGNEvogene Reports Fourth Quarter and Full Year 2023 Financial Results
Conference call and webcast: today, March 7, 2024, 9:00 am E.T. +1-888-407-2553 or +972-3- 9180608 I https://veidan.activetrail.biz/evogeneq4-2023 REHOVOT, Israel, March 7, 2024 /PRNewswire/ -- Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a leading computational biology company ta
Read more →EVGNEvogene Schedules Fourth Quarter 2023 Financial Results Release & Conference Call for March 7th, 2024
Conference call scheduled for 9:00 AM ET REHOVOT, Israel, Feb. 26, 2024 /PRNewswire/ -- Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a leading computational biology company targeting to revolutionize life-science product discovery and development across multiple market segments, an
Read more →EVGNEvogene Reports Third Quarter 2023 Financial Results
Conference call and webcast: today, November 15, 2023, 9:00 am ET REHOVOT, Israel, Nov. 15, 2023 /PRNewswire/ -- Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a leading computational biology company aiming to revolutionize the development of life-science-based products utilizing cut
Read more →EVGN▲ +7%on this news· ran to +20% by day 3
Evogene Schedules Third Quarter 2023 Financial Results Release & Conference Call for November 15, 2023
Conference call scheduled for 9:00 AM ET REHOVOT, Israel, Nov. 2, 2023 /PRNewswire/ -- Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a leading computational biology company targeting to revolutionize life-science product discovery and development across multiple market segments, ann
Read more →EVGNColors Farm, Evogene and Ben-Gurion University Collaborate to Establish Crustacean Gene Editing Technology
Leveraging a grant from the Israel Innovation Authority, the alliance sets out to improve crustacean traits including growth rate, disease resistance, and environmental adaptation. HAZEVA and REHOVOT, Israel, Oct. 31, 2023 /PRNewswire/ -- Colors Farm Ltd, a cutting-edge company
Read more →EVGN▼ -6%on this news
Evogene Provides Operational Update Amidst Current Security Situation in Israel
REHOVOT, Israel, Oct. 18, 2023 /PRNewswire/ -- Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a leading computational biology company targeting to revolutionize life-science product discovery and development across multiple market segments, today provides an update to its investors an
Read more →EVGN▼ -19.2%on this news
Evogene Reports Second Quarter 2023 Financial Results
Conference call and webcast: today, August 17, 2023, 9:00 am ET REHOVOT, Israel, Aug. 17, 2023 /PRNewswire/ -- Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a leading computational biology company aiming to revolutionize life-science-based product discovery and development utilizing
Read more →EVGNEvogene Schedules Second Quarter 2023 Financial Results Release & Conference Call for August 17, 2023
Conference call scheduled for 9:00 AM ET REHOVOT, Israel, Aug. 1, 2023 /PRNewswire/ -- Evogene Ltd. (Nasdaq: EVGN)(TASE: EVGN), a leading computational biology company targeting to revolutionize life-science product discovery and development across multiple market segments, anno
Read more →EVGNEvogene's ChemPass AI Tech-Engine is Introduced with New Breakthrough Machine Learning Technology for Target-Protein Discovery Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a leading computational biology company targeting to revolutionize life-science product discovery and...
The new application, TargetSelector, streamlines target-protein discovery and enables researchers in various industries to identify novel targets for innovative products REHOVOT, Israel, July 25, 2023 /PRNewswire/ -- Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a leading computatio
Read more →EVGN▼ -21.1%on this news
Evogene Announces Pricing of US$8,500,000 Registered Direct Offering
REHOVOT, Israel, July 17, 2023 /PRNewswire/ -- Evogene Ltd. ("Evogene") (Nasdaq: EVGN) (TASE: EVGN), a leading computational biology company aiming to revolutionize life-science-based product discovery and development utilizing cutting-edge computational biology technologies acro
Read more →EVGN▼ -5.3%on this news
Evogene Reports First Quarter 2023 Financial Results
Conference call and webcast: today, May 18, 2023, 9:00 am ET REHOVOT, Israel, May 18, 2023 /PRNewswire/ -- Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a leading computational biology company aiming to revolutionize life-science-based product discovery and development utilizing cut
Read more →EVGNEvogene Ag-Seed Division Awarded Prestigious €1.2M Horizon Grant to Develop Oil-Seed Crops with High CO2 Assimilation and Drought Tolerance
The grant under the EU Horizon Program was approved following the successful proof of concept from the previous program launched in 2016 REHOVOT, Israel, May 9, 2023 /PRNewswire/ -- The Ag-Seed Division of Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN) ("Evogene"), a leading computati
Read more →EVGNEvogene Schedules First Quarter 2023 Financial Results Release & Conference Call for May 18, 2023
Conference call scheduled for 9AM ET REHOVOT, Israel, May 4, 2023 /PRNewswire/ -- Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a leading computational biology company aiming to revolutionize life-science product development, announced today that it will release its financial result
Read more →EVGNEvogene Reports Fourth Quarter and Full Year 2022 Financial Results
Conference call and webcast: today, March 9, 2023, 9:00 am ET REHOVOT, Israel, March 9, 2023 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a leading computational biology company targeting to revolutionize life-science based product discovery and development utilizin
Read more →EVGNEvogene to Attend the Annual ROTH Investor Conference in California on March 13, 2023
REHOVOT, Israel, March 1, 2023 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a leading computational biology company focused on revolutionizing product discovery and development in multiple life-science based industries, today announced that it will attend and meeting
Read more →EVGNEvogene Schedules Fourth Quarter and Full Year 2022 Financial Results Release & Conference Call for March 9, 2023
Conference call scheduled for 9am ET REHOVOT, Israel, Feb. 27, 2023 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a leading computational biology company aiming to revolutionize life-science product development announced today that it will release its financial resul
Read more →EVGNEvogene to Receive $3.5 million Payment Related to Patent Portfolio under its Existing Seed Traits Collaboration with Bayer
REHOVOT, Israel, Dec. 8, 2022 /PRNewswire/ -- Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN) (the "Company", "Evogene"), a leading computational biology company targeting to revolutionize life-science product discovery and development across multiple market segments, announced today th
Read more →EVGNEvogene Schedules Third Quarter of 2022 Financial Results Release & Conference Call for November 17, 2022
Conference call scheduled for 9am ET REHOVOT, Israel, Nov. 7, 2022 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a leading computational biology company aiming to revolutionize life-science product development announced today that it will release its financial result
Read more →EVGNEvogene to Present at the LD Micro Main Event XV Investor Conference in Los Angeles
REHOVOT, Israel, Oct. 6, 2022 /PRNewswire/ -- Evogene Ltd. (Nasdaq: EVGN, TASE: EVGN) (the "Company", "Evogene"), a leading computational biology company targeting to revolutionize life-science product discovery and development across multiple market segments, announced today tha
Read more →EVGNEvogene to Present at the H.C. Wainwright 24th Annual Global Investment Conference
REHOVOT, Israel, Sept. 7, 2022 /PRNewswire/ -- Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN) (the "Company", "Evogene"), a leading computational biology company targeting to revolutionize life-science product discovery and development across multiple market segments, announced today t
Read more →EVGN▼ -13.3%on this news
Evogene Reports Second Quarter 2022 Financial Results
Conference call and webcast: today, August 31, 2022, 9:00 am ET REHOVOT, Israel, Aug. 31, 2022 /PRNewswire/ -- Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a leading computational biology company targeting to revolutionize life-science product discovery and development across multi
Read more →EVGNEvogene Financial Results and Earnings Announcement Schedule for the Second Quarter of 2022
REHOVOT, Israel, Aug. 2, 2022 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a leading computational biology company aiming to revolutionize life-science product development across several market segments, announced today that it will release its financial results for
Read more →EVGN▼ -8.2%on this news
Evogene Reports First Quarter 2022 Financial Results
Conference call and webcast: today, May 26, 2022, 9:00 am ET REHOVOT, Israel, May 26, 2022 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a leading computational biology company targeting to revolutionize life-science product discovery and development across multiple
Read more →EVGNEvogene Financial Results and Earnings Announcement Schedule for the First Quarter of 2022
REHOVOT, Israel, May 10, 2022 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a leading computational biology company aiming to revolutionize life-science product development across several market segments, announces today that it will release its financial results for
Read more →EVGNEvogene to Present at the Jefferies Virtual Synthetic Biology Week on March 23, 2022
REHOVOT, Israel, March 14, 2022 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN, TASE: EVGN), a leading computational biology company focused on revolutionizing product discovery and development in multiple life-science based industries, today announced that it will be attending the J
Read more →EVGN▲ +7.8%on this newsshared move
Evogene Reports Fourth Quarter and Full Year 2021 Financial Results
REHOVOT, Israel, March 10, 2022 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a leading computational biology company targeting to revolutionize life-science product discovery and development across multiple market segments, announced today its financial results for t
Read more →EVGNEvogene to Attend to World Agri-Tech Innovation Summit from March 22-23, 2022
REHOVOT, Israel, March 7, 2022 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a leading computational biology company focused on revolutionizing product discovery and development in multiple life-science based industries, today announced that it will be attending the W
Read more →EVGN▼ -9.9%on this newsshared move
Evogene to Attend the 34th Annual ROTH Investor Conference in Dana Point California Between March 13-15, 2022
REHOVOT, Israel, March 3, 2022 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a leading computational biology company focused on revolutionizing product discovery and development in multiple life-science based industries, today announced that it will present at the 34t
Read more →EVGNEvogene Financial Results and Earnings Announcement Schedule for the Full Year and Fourth Quarter of 2021
REHOVOT, Israel, Feb. 15, 2022 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a leading computational biology company aiming to revolutionize life-science product development across several market segments, announces today that it will release its financial results for
Read more →EVGN▼ -6.7%on this news
Evogene to Participate in Edison Group
REHOVOT, Israel, Jan. 19, 2022 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), announced today it is participating in Edison Group's Open House Event, scheduled to take place virtually this month. For more information on the event and details on how to register, please
Read more →EVGNEvogene Reports Third Quarter 2021 Financial Results
REHOVOT, Israel, Nov. 17, 2021 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a leading computational biology company targeting to revolutionize life-science product discovery and development across multiple market segments, announced today its financial results for th
Read more →EVGNEvogene Announces Participation in the Second Research Period of the CRISPR-IL Consortium
REHOVOT, Israel, Nov. 10, 2021 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a leading computational biology company targeting to revolutionize life-science product development across several market segments, announced today that it has been informed by the Israeli In
Read more →EVGNEvogene Financial Results and Earnings Announcement Schedule for the Third Quarter of 2021
REHOVOT, Israel, Oct. 27, 2021 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a leading computational biology company aiming to revolutionize life-science product development across several market segments, announces today that it will release its financial results for
Read more →EVGN▼ -5.5%on this news
Evogene to Present at Cantor Virtual Global Healthcare Conference, September 2021
REHOVOT, Israel, Sept. 14, 2021 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a leading computational predictive biology company aiming to revolutionize life-science product development acros\s several market segments, announced today that Mr. Ofer Haviv, Evogene's Pr
Read more →EVGNEvogene to Present at H.C. Wainwright 23rd Annual Global Investment Conference - 2021
REHOVOT, Israel, Sept. 1, 2021 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a leading computational biology company aiming to revolutionize life-science product development across several market segments, announced today that Ofer Haviv, Evogene's President and CEO,
Read more →EVGNEvogene Reports Second Quarter 2021 Financial Results
REHOVOT, Israel, Aug. 11, 2021 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a leading computational biology company targeting to revolutionize life-science product discovery and development across several market segments, announced today its financial results for the
Read more →EVGNEvogene to Present at Jefferies Virtual Industrials Conference, 2021
REHOVOT, Israel, July 29, 2021 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a leading computational biology company aiming to revolutionize life-science product development across several market segments, announced today that Ofer Haviv, Evogene's President and CEO,
Read more →EVGNEvogene Financial Results and Earnings Announcement Schedule for the Second Quarter of 2021
REHOVOT, Israel, July 28, 2021 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a leading computational biology company aiming to revolutionize life-science product development across several market segments, announces today that it will release its financial results for
Read more →EVGNEvogene Announces Ms. Sarit Firon to become Evogene
REHOVOT, Israel, June 23, 2021 /PRNewswire/ --Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a leading computational biology company aiming to revolutionize life-science product development across several market segments, announced today that its Board of Directors has resolved to app
Read more →EVGNEvogene Reports First Quarter 2021 Financial Results
REHOVOT, Israel, May 26, 2021 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a leading computational biology company targeting to revolutionize life-science product discovery and development across several market segments, announces today its financial results for the
Read more →EVGNEvogene Financial Results and Earnings Announcement Schedule for the First Quarter of 2021
REHOVOT, Israel, May 12, 2021 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a leading computational biology company aiming to revolutionize life-science product development across several market segments, announces today that it will release its financial results for
Read more →EVGNEvogene to Hold Virtual Investor & Analyst Days
REHOVOT, Israel, April 7, 2021 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN), (TASE: EVGN), a leading computational biology company today announced that it will hold virtual investor and analyst days, in both Hebrew and English, via Zoom webinars. The meetings will feature key-not
Read more →EVGNEvogene Reports Fourth Quarter and Full Year 2020 Financial Results
REHOVOT, Israel, March 3, 2021 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN.TA), a leading computational biology company targeting to revolutionize life-science product discovery and development across several market segments, announces today its financial results for
Read more →EVGNEvogene Financial Results and Earnings Announcement Schedule for the Fourth Quarter and Full Year of 2020
REHOVOT, Israel, Feb. 17, 2021 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a leading computational biology company aiming to revolutionize life-science product development across several market segments, announces today that it will release its financial results for
Read more →EVGNEvogene Provides 2020 Year-End Update for CRISPR-IL Consortium
REHOVOT, Israel, Jan. 5, 2021 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN), (TASE: EVGN), a leading computational biology company targeting to revolutionize life-science product development across several market segments, provided today a year-end update for the CRISPR-IL consorti
Read more →EVGNEvogene Reports Third Quarter 2020 Financial Results
REHOVOT, Israel, Nov. 18, 2020 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN), (TASE: EVGN), a leading computational biology company targeting to revolutionize life-science product development across several market segments, announced today its financial results for the third quarte
Read more →EVGNEvogene Announces Closing of $12 Million Registered Direct Offering
REHOVOT, Israel, Nov. 4, 2020 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN), (TASE: EVGN), a leading computational biology company focused on revolutionizing product discovery and development in multiple life-science based industries, including human health and agriculture, today a
Read more →EVGNEvogene Financial Results and Earnings Announcement Schedule for the Third Quarter of 2020
REHOVOT, Israel, Nov. 2, 2020 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a leading computational biology company aiming to revolutionize life-science product development across several market segments, announces today that it will release its financial results for
Read more →EVGNEvogene Prices $12 Million Registered Direct Offering
REHOVOT, Israel, Oct. 30, 2020 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN), (TASE: EVGN), a leading computational biology company focused on revolutionizing product discovery and development in multiple life-science based industries, including human health and agriculture, today
Read more →EVGNEvogene Announces Participation at the H.C. Wainwright 22nd Annual Global Investment Conference on September 14-16, 2020 (Virtual Conference)
REHOVOT, Israel, Sept. 9, 2020 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN, TASE: EVGN.TA), a leading computational biology company focused on revolutionizing product discovery and development in multiple life-science based industries, including human health and agriculture, today
Read more →EVGNEvogene Announces $10 Million Equity Led Investment by ARK Investment Management, LLC
REHOVOT, Israel, Sept. 1, 2020 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN.TA), a leading computational biology company focused on revolutionizing product discovery and development in multiple life-science based industries, including human health and agriculture, toda
Read more →EVGNEvogene Reports Second Quarter 2020 Financial Results
REHOVOT, Israel, Aug. 5, 2020 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN.TA), a leading computational biology company targeting to revolutionize life-science product development across several market segments, announced today its financial results for the second quar
Read more →EVGNEvogene to Present at Jefferies Virtual 2020 Industrials Conference
REHOVOT, Israel, July 29, 2020 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN.TA), a leading artificial intelligence company targeting to revolutionize life-science product development across several market segments utilizing computational biology, announces today that O
Read more →EVGNEvogene Financial Results and Earnings Announcement Schedule for the Second Quarter of 2020
REHOVOT, Israel, July 15, 2020 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN.TA), a leading computational biology company targeting to revolutionize life-science product development across several market segments, announces today that it will release its financial resul
Read more →EVGNEvogene to Participate in CRISPR-IL Consortium to Provide End-to-End Artificial Intelligence System for Genome-Editing
REHOVOT, Israel, June 3, 2020 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN.TA), a leading computational biology company targeting to revolutionize life-science product development across several market segments, announced today its participation in the CRISPR-IL consor
Read more →EVGNEvogene Reports First Quarter 2020 Financial Results
REHOVOT, Israel, May 26, 2020 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN.TA), a leading computational biology company targeting to revolutionize life-science product development across several market segments, announced today its financial results for the first quart
Read more →EVGNEvogene Launches Its New Branding to Reflect the Company
REHOVOT, Israel, May 20, 2020 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN.TA), a leading computational biology company targeting to revolutionize life-science product development across several market segments, announces today its rebranding. The new corporate identit
Read more →EVGNEvogene Financial Results and Earnings Announcement Schedule for the First Quarter of 2020
REHOVOT, Israel, May 7, 2020 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN.TA), a leading biotechnology company aiming to revolutionize the development of novel products for life-science based industries by utilizing cutting edge computational biology technologies, anno
Read more →EVGNEvogene Publishes Letter to Shareholders
REHOVOT, Israel, May 5, 2020 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN.TA), a leading biotechnology company aiming to revolutionize the development of novel products for life-science based industries, by utilizing cutting edge computational biology technologies, ann
Read more →EVGNEvogene Files Annual Report for the Year Ended December 31, 2019
REHOVOT, Israel, April 30, 2020 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a leading biotechnology company aiming to revolutionize the development of novel products for life-science based industries, announced today that it has filed its annual report on Form 20-F
Read more →EVGNEvogene Reports Fourth Quarter and Full Year 2019 Financial Results
REHOVOT, Israel, March 4, 2020 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN.TA), a leading company in leveraging computational biology to design novel products for life-science-based industries, announces today its financial results for the fourth quarter and full year
Read more →EVGNEvogene to Attend in Bank of America 2020 Global Agriculture and Materials Conference
REHOVOT, Israel, Feb. 25, 2020 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN.TA), a leading company in leveraging computational biology to design novel products for life-science-based industries including: human health, agriculture and industrial applications, announces
Read more →EVGNEvogene Financial Results for the Fourth Quarter and Full Year of 2019 Earnings Announcement Schedule
REHOVOT, Israel, Feb. 12, 2020 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a leading company in leveraging computational biology to design novel products for life-science-based industries including: human health, agriculture and industrial applications, announces to
Read more →EVGNEvogene Reports Third Quarter 2019 Financial Results
REHOVOT, Israel, Nov. 13, 2019 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a leading biotechnology company developing novel products for life science markets, announces today its financial results for the third quarter, ending September 30, 2019. Ofer Haviv, Evogen
Read more →EVGNEvogene Financial Results for the Third Quarter of 2019 Earnings Announcement Schedule
REHOVOT, Israel, Oct. 23, 2019 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a leading biotechnology company developing novel products for life science markets, announced today that it will release its financial results for the third quarter of 2019 on Wednesday, Nove
Read more →EVGNEvogene Reports Second Quarter of 2019 Financial Results
REHOVOT, Israel, July 31, 2019 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a leading biotechnology company developing novel products for life science markets, announced today its financial results for the second quarter ending June 30, 2019. Ofer Haviv, Evogene's P
Read more →EVGNEvogene Amends its Collaboration Agreement With Bayer to Include Genome Editing Targets
REHOVOT, Israel, July 16, 2019 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a leading biotechnology company developing novel products for life science markets, announces today that after achieving positive results, its corn disease resistance research collaboration w
Read more →EVGNEvogene to Present at Jefferies 2019 Industrials Conference
REHOVOT, Israel, July 15, 2019 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a leading biotechnology company developing novel products for life science markets, announced today that Ofer Haviv, Evogene's President and CEO, will present at the Jefferies 2019 Industrial
Read more →EVGNEvogene Financial Results for the Second Quarter of 2019 Earnings Announcement Schedule
REHOVOT, Israel, July 11, 2019 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN), (TASE: EVGN), a leading biotechnology company developing novel products for life science markets, announced today that it will release its financial results for the second quarter of 2019 on Wednesday, Ju
Read more →EVGNEvogene Reports First Quarter of 2019 Financial Results
REHOVOT, Israel, May 28, 2019 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a leading biotechnology company developing novel products for life science markets, announced today its financial results for the first quarter ending March 31, 2019. Ofer Haviv, Evogene's Pr
Read more →EVGNEvofuel to Participate in the 2019 International Castor Oil Association - ICOA Conference
REHOVOT, Israel, May 21, 2019 /PRNewswire/ -- Evofuel Ltd., a company focused on securing the global demand for stable castor oil supply and a wholly owned subsidiary of Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), announced today that its CEO, Mr. Assaf Dotan, will present at 2019
Read more →EVGNEvogene Financial Results for the First Quarter of 2019
REHOVOT, Israel, May 7, 2019 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a leading biotechnology company developing novel products for life science markets, announced today that it will release its financial results for the first quarter of 2019 on Tuesday, May 28,
Read more →EVGNEvogene Files Annual Report for the Year Ended December 31, 2018
REHOVOT, Israel, April 30, 2019 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a leading biotechnology company developing novel products for life science markets, announced today that it has filed its annual report on Form 20-F for the fiscal year ended December 31, 20
Read more →EVGNBiomica Initiates Pre-clinical Studies in Its Immuno-oncology Program
REHOVOT, Israel, April 16, 2019 /PRNewswire/ -- Biomica, an emerging biopharmaceutical company developing innovative microbiome-based therapeutics, and a subsidiary of Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), announced today the initiation of pre-clinical studies for BMC-121 & B
Read more →EVGNEvogene to Develop Next Generation Medical Cannabis Products Through New Subsidiary - Canonic Ltd
REHOVOT, Israel, April 3, 2019 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a leading biotechnology company developing novel products for life science markets, announced today that it has established a new subsidiary – Canonic Ltd – to develop next generation medical
Read more →EVGNEvogene to Participate in the World Agritech, Innovation Summit in San Francisco in March 19-20, 2019
REHOVOT, Israel, March 14, 2019 /PRNewswire/ -- - Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a leading biotechnology company developing novel products for life science markets, announced today that Evogene will be participating in the World Agritech Innovation Summit to take plac
Read more →EVGNAgPlenus - Evogene
REHOVOT, Israel, March 14, 2019 /PRNewswire/ -- AgPlenus, a subsidiary of Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), designing effective and sustainable crop protection products by leveraging predictive biology, announced today the nomination of leading industry experts from the f
Read more →EVGNEvogene Reports Fourth Quarter and Full Year 2018 Financial Results
REHOVOT, Israel, March 13, 2019 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a leading biotechnology company developing novel products for life science markets, announced today its financial results for the fourth quarter and full year ending December 31, 2018. Evog
Read more →EVGNEvogene Fourth Quarter and Full Year of 2018 Earnings Announcement Schedule
REHOVOT, Israel, Feb. 28, 2019 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a leading biotechnology company developing novel products for life science markets, announced today that it will release its financial results for the fourth quarter and full year of 2018 on
Read more →EVGNEvogene Announces Establishment of Ag-Biologicals Subsidiary - LaVie Bio Ltd.
REHOVOT, Israel, Feb. 26, 2019 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a leading biotechnology company developing novel products for life science markets, announced today the establishment of a new subsidiary – LaVie Bio Ltd (LaVie). The new company will focus o
Read more →EVGNEvogene Appoints Dr. Adrian Percy to Its Board of Directors
REHOVOT, Israel, Feb. 4, 2019 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a leading biotechnology company developing novel products for life science markets, announced today the appointment of Dr. Adrian Percy to its board of directors. Dr. Percy has more than 25 ye
Read more →EVGNEvogene and TMG Announce Collaboration to Develop Nematode Resistant Soybean through Genome Editing
REHOVOT, Israel & CAMB , Brazil, Dec. 18, 2018 (GLOBE NEWSWIRE) -- Evogene Ltd. (NASDAQ, TASE: EVGN), a leading biotechnology company developing novel products for life science markets & TMG - Tropical Melhoramento & Genética S/A, a leading plant breeding company aiming to develo
Read more →EVGNEvogene’s Leading Insect Control Genes Demonstrate Effectiveness Against Insects with Resistance to Current Commercial Solutions
REHOVOT, Israel, Nov. 27, 2018 (GLOBE NEWSWIRE) -- Evogene Ltd. (NASDAQ, TASE: EVGN), a leading biotechnology company developing novel products for life science markets, announces today that a well-recognized external laboratory and in-house testing had confirmed that leading Evo
Read more →EVGNEvogene Announces Establishment of Ag-Chemicals Subsidiary – AgPlenus Ltd.
Evogene’s activities relating to design and development of effective and safe next generation agro-chemical products transferred to new subsidiary REHOVOT, Israel, Nov. 19, 2018 (GLOBE NEWSWIRE) -- Evogene Ltd. (NASDAQ, TASE: EVGN), a leading biotechnology company developing no
Read more →EVGNEvogene Reports Third Quarter 2018 Financial Results
REHOVOT, Israel, Nov. 14, 2018 (GLOBE NEWSWIRE) -- Conference call and webcast, today at 9:00 am Eastern Time Evogene Ltd. (NASDAQ, TASE: EVGN), a leading biotechnology company developing novel products for life science markets, announced today its financial results for the thir
Read more →EVGNEvogene Financial Results for the Third Quarter of 2018 Earnings Announcement Schedule
REHOVOT, Israel, Oct. 24, 2018 (GLOBE NEWSWIRE) -- Evogene Ltd. (NASDAQ, TASE: EVGN), a leading biotechnology company developing novel products for life science markets, announced today that it will release its financial results for the third quarter of 2018 on Wednesday, Novembe
Read more →EVGNEvogene Announces a Significant Milestone in its Next Generation Herbicide Pipeline
REHOVOT, Israel, Sept. 05, 2018 (GLOBE NEWSWIRE) -- Evogene Ltd. (NASDAQ, TASE: EVGN), a leading biotechnology company developing novel products for life science markets, announced today a significant milestone in its next generation herbicide pipeline. Evogene’s Ag-Chemicals div
Read more →EVGNEvogene Reports Second Quarter 2018 Financial Results
REHOVOT, Israel, Aug. 08, 2018 (GLOBE NEWSWIRE) -- Evogene Ltd. (NASDAQ, TASE: EVGN), a leading biotechnology company developing novel products for life science markets, announced today its financial results for the second quarter ending June 30, 2018. Ofer Haviv, Evogene's Pres
Read more →EVGNEvogene Financial Results for the Second Quarter of 2018
REHOVOT, Israel, July 18, 2018 (GLOBE NEWSWIRE) -- Evogene Ltd. (NASDAQ:EVGN) (TASE:EVGN), a leading biotechnology company developing novel products for life science markets, announced today that it will release its financial results for the second quarter of 2018 on Wednesday, A
Read more →EVGNEvogene and IMAmt Enter a Collaboration in the Field of Insect Resistance Traits in Cotton
REHOVOT, Israel and CUIAB /MT, Brazil, July 17, 2018 (GLOBE NEWSWIRE) -- Evogene Ltd. (NASDAQ:EVGN) (TASE:EVGN), a leading biotechnology company developing novel products for life science markets, and Instituto Mato-grossense do Algodão (IMAmt), a leading developer and marketer o
Read more →EVGNEvogene Announces Positive Yield Results in its Bio-Stimulant Program for Wheat
REHOVOT, Israel, July 10, 2018 (GLOBE NEWSWIRE) -- Evogene Ltd. (NASDAQ:EVGN) (TASE:EVGN), a leading biotechnology company developing novel products for life science markets, announced today that its Ag-Biologicals division has achieved positive yield results leading to phase adv
Read more →EVGNEvogene Reports First Quarter 2018 Financial Results
REHOVOT, Israel, May 29, 2018 (GLOBE NEWSWIRE) -- Evogene Ltd. (NASDAQ:EVGN) (TASE:EVGN), a leading biotechnology company developing novel products for life science markets, announced today its financial results for the first quarter ending March 31, 2018. Ofer Haviv, Evogene's
Read more →EVGNEvogene Financial Results for the First Quarter of 2018 Earnings Announcement Schedule
REHOVOT, Israel, May 10, 2018 (GLOBE NEWSWIRE) -- Evogene Ltd. (NASDAQ:EVGN) (TASE:EVGN), a leading biotechnology company developing novel products for life science markets, announced today that it will release its financial results for the first quarter of 2018 on Tuesday, May 2
Read more →EVGNEvogene and Marrone Bio Innovations Announce Phase Advancement in their Insect Control Collaboration
REHOVOT, Israel and DAVIS, Calif., May 08, 2018 (GLOBE NEWSWIRE) -- Evogene Ltd. (NASDAQ:EVGN) (TASE:EVGN), a leading biotechnology company developing novel products for life science markets, and Marrone Bio Innovations Inc. (MBI), (NASDAQ:MBII), a leading global provider of bio-
Read more →EVGNEvogene Files Annual Report for the Year Ended December 31, 2017
REHOVOT, Israel, April 01, 2018 (GLOBE NEWSWIRE) -- Evogene Ltd. (NASDAQ:EVGN) (TASE:EVGN), a leading biotechnology company developing novel products for life science markets through the use of a unique Computational Predictive Biology (CPB) platform, announced today that it has
Read more →EVGNEvogene Reports Fourth Quarter and Full Year 2017 Financial Results
REHOVOT, Israel, Feb. 28, 2018 (GLOBE NEWSWIRE) -- Evogene Ltd. (NASDAQ:EVGN) (TASE:EVGN), a leading biotechnology company developing novel products for life science markets through the use of a unique Computational Predictive Biology (CPB) platform, announced today its financial
Read more →EVGNEvogene Announces Positive Results in its Novel Mode-of-Action Herbicide Program
REHOVOT, Israel, Feb. 27, 2018 (GLOBE NEWSWIRE) -- Evogene Ltd. (NASDAQ:EVGN)) (TASE:EVGN), a leading biotechnology company developing novel products for life science markets through the use of a unique Computational Predictive Biology (CPB) platform, announced today that its Ag-
Read more →EVGNEvogene Financial Results for the Fourth Quarter and Full Year 2017 Earnings Announcement Schedule
REHOVOT, Israel, Feb. 12, 2018 (GLOBE NEWSWIRE) -- Evogene Ltd. (NASDAQ:EVGN)(TASE:EVGN), a leading biotechnology company developing novel products for life science markets through the use of a unique computational predictive biology platform, announced today that it will release
Read more →EVGNEvogene to Participate in Israeli Consortium to Develop Phenotyping Tools and Systems for Precision Agriculture
REHOVOT, Israel, Jan. 29, 2018 (GLOBE NEWSWIRE) -- Evogene Ltd. (NASDAQ:EVGN) (TASE:EVGN), a leading biotechnology company developing novel products for life science markets through the use of a unique computational predictive biology platform, announced today its participation i
Read more →EVGNEvogene Announces Positive 2nd Year Field Trial Results in Corn Bio-Stimulant Ag-Biologicals Program
REHOVOT, Israel, Jan. 10, 2018 (GLOBE NEWSWIRE) -- Evogene Ltd. (NASDAQ:EVGN) (TASE:EVGN), a leading biotechnology company developing novel products for life science markets through the use of a proprietary computational predictive biology platform, announced today highly promisi
Read more →EVGNEvogene Reports Third Quarter 2017 Financial Results
REHOVOT, Israel, Nov. 22, 2017 (GLOBE NEWSWIRE) -- Evogene Ltd. (NASDAQ:EVGN) (TASE:EVGN), a leading biotechnology company developing novel products for life science markets through the use of a unique computational predictive biology platform, announced today its financial resul
Read more →EVGNEvogene Financial Results for the Third Quarter of 2017 Earnings Announcement Schedule
REHOVOT, Israel, Nov. 02, 2017 (GLOBE NEWSWIRE) -- Evogene Ltd. (NASDAQ:EVGN) (TASE:EVGN), a leading biotechnology company developing novel products for life science markets through the use of a unique computational predictive biology platform, announced today that it will releas
Read more →EVGNEvogene Announces Revised and Expanded Market Focus and New Corporate Structure
REHOVOT, Israel, Oct. 30, 2017 (GLOBE NEWSWIRE) -- Evogene Ltd. (NASDAQ:EVGN) (TASE:EVGN), a leading biotechnology company developing novel products for life science markets through the use of a unique computational predictive biology platform, announced today that it has revised
Read more →EVGNEvogene & Rahan Meristem announce positive results in 2nd year field trials addressing Black Sigatoka disease in banana and the utilization of the results for genome editing
REHOVOT and ROSH HANIKRA, Israel, Sept. 26, 2017 (GLOBE NEWSWIRE) -- Evogene Ltd. (NASDAQ:EVGN) (TASE:EVGN), a leading company for the improvement of crop productivity, and Rahan Meristem (1998) Ltd., a leading fruit biotechnology and breeding company, announced today positive re
Read more →EVGNEvogene to Present at the 26th Asian-Pacific Weed Science Society Conference
REHOVOT, Israel, Aug. 23, 2017 (GLOBE NEWSWIRE) -- Evogene Ltd., (NASDAQ:EVGN) (TASE:EVGN), a leading company for the improvement of crop productivity, announced today that the R&D director of its Ag-Chemicals activity area, Dr. Boaz Inbal, will present the company’s biology-driv
Read more →EVGNEvogene Reports Second Quarter 2017 Financial Results
REHOVOT, Israel, Aug. 10, 2017 (GLOBE NEWSWIRE) -- Evogene Ltd. (NASDAQ:EVGN) (TASE:EVGN), a leading company for the improvement of crop productivity and economics, announced today its financial results for the second quarter ended June 30, 2017. Ofer Haviv, Evogene's President
Read more →EVGNEvogene Financial Results for the Second Quarter of 2017 Earnings Announcement Schedule
REHOVOT, Israel, July 20, 2017 (GLOBE NEWSWIRE) -- Evogene Ltd. (NASDAQ:EVGN) (TASE:EVGN), a leading company for the improvement of crop productivity and economics for food, feed and biofuel industries, announced today that it will release its financial results for the second qua
Read more →EVGNEvogene Achieves Important Milestone in Monsanto Crop Disease Collaboration
Positive Fusarium resistance achieved with Evogene discovered genes Evogene also announces completion of candidate gene discovery stage in Monsanto yield and abiotic stress collaboration REHOVOT, Israel, July 11, 2017 (GLOBE NEWSWIRE) -- Evogene Ltd. (NASDAQ:EVGN) (TASE:EVGN),
Read more →EVGNEvogene announces positive results in Insect Control Seed Trait Program and advancement to Phase-I of first toxin against Western corn rootworm
REHOVOT, Israel, June 20, 2017 (GLOBE NEWSWIRE) -- Evogene Ltd. (NASDAQ:EVGN) (TASE:EVGN), a leading company for the improvement of crop productivity and economics for food, feed and fuel, announced today the advancement of a gene displaying insecticidal activity against Western
Read more →EVGNEvogene Reports First Quarter 2017 Financial Results
REHOVOT, Israel, May 17, 2017 (GLOBE NEWSWIRE) -- Evogene Ltd. (NASDAQ:EVGN) (TASE:EVGN), a leading company for the improvement of crop productivity and economics for food, feed and fuel, announced today its financial results for the first quarter ended March 31, 2017. Ofer Havi
Read more →EVGNEvogene Files Annual Report for the Year Ended December 31, 2016
REHOVOT, Israel, May 04, 2017 (GLOBE NEWSWIRE) -- Evogene Ltd. (NASDAQ:EVGN) (TASE:EVGN), a leading company for the improvement of crop productivity and economics for food, feed and fuel, announced today that it has filed its annual report on Form 20-F for the fiscal year ended D
Read more →EVGNEvogene Financial Results for the First Quarter of 2017 Earnings Announcement Schedule
REHOVOT, Israel, April 26, 2017 (GLOBE NEWSWIRE) -- Evogene Ltd. (NASDAQ:EVGN) (TASE:EVGN), a leading biotechnology company for the improvement of crop productivity, announced today that it will release its financial results for the first quarter of 2017 on Wednesday, May 17, 201
Read more →EVGNEvogene to Present Innovative Approach for Improving Cannabis for Medical Needs at CannaTech Summit
REHOVOT, Israel, March 07, 2017 (GLOBE NEWSWIRE) -- Evogene Ltd. (NASDAQ:EVGN) (TASE:EVGN), a leading company for the improvement of crop productivity and economics for food, feed and fuel, announced today that Mr. Yuval Ben-Galim, Evogene's COO, will present at the CannaTech 201
Read more →EVGNEvogene Reports Fourth Quarter and Full Year 2016 Financial Results
REHOVOT, Israel, Feb. 27, 2017 (GLOBE NEWSWIRE) -- Evogene Ltd. (NASDAQ:EVGN) (TASE:EVGN), a leading company for the improvement of crop productivity, announced today its financial results for the fourth quarter and year ended December 31, 2016. Ofer Haviv, Evogene's President a
Read more →EVGNEvogene and ICL Innovation Sign Collaboration for Development of Crop Enhancers
- R&D collaboration will focus on discovery of products for improvement of nutrient use efficiency in selected crops - REHOVOT, and TEL AVIV, Israel, Feb. 14, 2017 (GLOBE NEWSWIRE) -- Evogene Ltd. (NASDAQ:EVGN) (TASE:EVGN), a leading company for the improvement of crop productiv
Read more →EVGNEvogene Fourth Quarter and Full Year 2016 Earnings Announcement Schedule
REHOVOT, Israel, Feb. 13, 2017 (GLOBE NEWSWIRE) -- Evogene Ltd. (NASDAQ:EVGN) (TASE:EVGN), a leading biotechnology company for the improvement of crop productivity, announced today that it will release its financial results for the fourth quarter and full year 2016 on Monday, Feb
Read more →EVGNEvogene to Transfer Stock Exchange Listing to NASDAQ
REHOVOT, Israel, Dec. 20, 2016 (GLOBE NEWSWIRE) -- Evogene Ltd. (NYSE:EVGN) (TASE:EVGN), a leading company for the improvement of crop productivity and economics for the food, feed and fuel industries, announced today that it will transfer its stock exchange listing to the NASDAQ
Read more →EVGNEvogene Reports Third Quarter 2016 Financial Results
REHOVOT, Israel, Nov. 21, 2016 (GLOBE NEWSWIRE) -- Evogene Ltd. (NYSE:EVGN) (TASE:EVGN), a leading company for the improvement of crop productivity and economics for the food, feed and fuel industries, announced today its financial results for the third quarter and nine months en
Read more →EVGNEvogene Announces Positive Field Trial Results in Ag-biologicals Program
REHOVOT, Israel, Nov. 16, 2016 (GLOBE NEWSWIRE) -- Evogene Ltd. (NYSE:EVGN) (TASE:EVGN), a leading company for the improvement of crop productivity and economics for the food, feed and fuel industries, announced today positive field trial results conducted in Israel from its Ag-b
Read more →EVGNEvogene Third Quarter 2016 Earnings Announcement Schedule
REHOVOT, Israel, Nov. 02, 2016 (GLOBE NEWSWIRE) -- Evogene Ltd. (NYSE:EVGN) (TASE:EVGN), a leading biotechnology company for the improvement of crop productivity, announced today that it will release its financial results for the third quarter of 2016 on Monday, November 21, 2016
Read more →EVGNEvogene and IMAmt Sign Collaboration for Genomic Promoter Discovery and Validation in Cotton
REHOVOT, Israel and CUIAB , Brazil, Oct. 19, 2016 (GLOBE NEWSWIRE) -- Evogene Ltd. (NYSE:EVGN) (TASE:EVGN), a leading biotechnology company for the improvement of crop productivity, and Instituto Mato-grossense do Algodão (IMAmt), a leading developer and marketer of cotton seeds,
Read more →EVGNEvogene Announces Joint Microbial Diversity Activity with University of Missouri
REHOVOT, Israel, Sept. 13, 2016 (GLOBE NEWSWIRE) -- Evogene Ltd. (NYSE:EVGN) (TASE:EVGN), a leading biotechnology company for the improvement of crop productivity for the food, feed and fuel industries, today announced it has entered into an agreement with the University of Misso
Read more →EVGNEvogene Announces Participation at the 18th Annual Rodman & Renshaw Global Investment Conference in New York City September 11-13th, 2016
REHOVOT, Israel, Sept. 01, 2016 (GLOBE NEWSWIRE) -- Evogene Ltd. (NYSE:EVGN) (TASE:EVGN), a leading biotechnology company for the improvement of crop productivity for the food, feed and fuel industries, today announced it will be featured as a presenting company at the 18th Annua
Read more →EVGNEvogene Appoints a New Member to Board of Directors and a New Chief Operating Officer
- Appointment of Ms. Sarit Firon adds substantial financial expertise to Board - - Mr. Yuval Ben-Galim to bring extensive operational and computational technology experience to Company management - REHOVOT, Israel, Aug. 11, 2016 (GLOBE NEWSWIRE) -- Evogene Ltd. (NYSE:EVGN) (TAS
Read more →EVGNEvogene Reports Second Quarter 2016 Financial Results
REHOVOT, Israel, Aug. 11, 2016 (GLOBE NEWSWIRE) -- Evogene Ltd. (NYSE:EVGN) (TASE:EVGN), a leading biotechnology company for the improvement of crop productivity and economics for the food, feed and fuel industries, announced today its financial results for the quarter and six mo
Read more →EVGNEvogene to Participate at Piper Jaffray Global Agriculture Symposium
REHOVOT, Israel, Aug. 01, 2016 (GLOBE NEWSWIRE) -- Evogene Ltd. (NYSE:EVGN) (TASE:EVGN), a leading biotechnology company for the improvement of crop productivity for the food, feed and fuel industries, announced today that Assaf Kacen, Chief Operating Officer, will participate at
Read more →EVGNEvogene Second Quarter 2016 Earnings Announcement Schedule
REHOVOT, Israel, July 25, 2016 (GLOBE NEWSWIRE) -- Evogene Ltd. (NYSE:EVGN) (TASE:EVGN), a leading biotechnology company for the improvement of crop productivity, announced today that it will release its financial results for the second quarter of 2016 on Thursday, August 11, 201
Read more →EVGNEvogene to Present at Crops and Chemicals 2016 Conference
REHOVOT, Israel, July 13, 2016 (GLOBE NEWSWIRE) -- Evogene Ltd. (NYSE:EVGN) (TASE:EVGN), a leading biotechnology company for the improvement of crop productivity, today announced that its Chief Scientific Officer, Dr. Eyal Emmanuel, will present initial results from the Company’s
Read more →EVGNEvogene Reports Financial Results for the First Quarter of 2016
REHOVOT, Israel, May 19, 2016 (GLOBE NEWSWIRE) -- Evogene Ltd. (NYSE:EVGN) (TASE:EVGN), a leading company for the improvement of crop productivity and economics for food, feed and fuel, announced today its financial results for the first quarter ended March 31, 2016. Ofer Haviv,
Read more →EVGNEvogene and Marrone Bio Innovations Disclose Positive Results in Insect Control Collaboration
REHOVOT, Israel and DAVIS, Calif., May 16, 2016 (GLOBE NEWSWIRE) -- Evogene Ltd. (NYSE:EVGN) (TASE:EVGN), a leading company for the improvement of crop productivity and economics for food, feed and fuel, and Marrone Bio Innovations Inc. (MBI), (NASDAQ:MBII), a leading global prov
Read more →EVGNEvogene to Present the Potential of Integrating Novel Genome Editing Technology with its Core Capabilities for Improved Seed Traits at Plant Genomics Congress
REHOVOT, Israel, May 03, 2016 (GLOBE NEWSWIRE) -- Evogene Ltd. (NYSE:EVGN) (TASE:EVGN), a leading company for the improvement of crop productivity and economics for food, feed and fuel, announced today that it will present the potential of integrating genome editing revolutionary
Read more →EVGNEvogene’s First Quarter 2016 Earnings Announcement Schedule
REHOVOT, Israel, May 02, 2016 (GLOBE NEWSWIRE) -- Evogene Ltd. (NYSE:EVGN) (TASE:EVGN), a leading company for the improvement of crop productivity and economics for the food, feed and biofuel industries, announced today that it will release its financial results for the first qua
Read more →EVGNEvogene Files Annual Report for the Year Ended December 31, 2015
REHOVOT, Israel, April 25, 2016 (GLOBE NEWSWIRE) -- Evogene Ltd. (NYSE:EVGN) (TASE:EVGN), a leading company for the improvement of crop productivity and economics for food, feed and fuel, announced today that it has filed its annual report on Form 20-F for the fiscal year ended D
Read more →EVGNEvogene Selected for Photosynthesis Research Consortium within European Horizon 2020 Program
REHOVOT, Israel, April 19, 2016 (GLOBE NEWSWIRE) -- Evogene Ltd. (NYSE:EVGN) (TASE:EVGN), a leading company for the improvement of crop productivity and economics for the food feed and biofuel industries, announced today that it is participating in a consortium for research in ph
Read more →EVGNEvogene Reports Fourth Quarter and Full Year 2015 Financial Results
REHOVOT, Israel, March 01, 2016 (GLOBE NEWSWIRE) -- Evogene Ltd. (NYSE:EVGN) (TASE:EVGN), a leading company for the improvement of crop productivity and economics for food, feed and fuel, announced today its financial results for the fourth quarter and year ended December 31, 201
Read more →EVGNEvogene Discloses Positive Results in Yield Improvement Collaboration With Monsanto Utilizing Novel 'Trait-First' Methodology
REHOVOT, Israel, Feb. 23, 2016 (GLOBE NEWSWIRE) -- Evogene Ltd. (NYSE:EVGN) (TASE:EVGN), a leading company for the improvement of crop productivity and economics for the food, feed and biofuel industries announced today positive results from the testing of a set of the Company's
Read more →EVGNEvogene’s Fourth Quarter and Full Year 2015 Earnings Announcement Schedule
REHOVOT, Israel, Feb. 09, 2016 (GLOBE NEWSWIRE) -- Evogene Ltd. (NYSE:EVGN) (TASE:EVGN), a leading company for the improvement of crop productivity and economics for the food, feed and biofuel industries, announced today that it will release its financial results for the fourth q
Read more →EVGNEvogene Appoints Eyal Leibovitz as Chief Financial Officer
REHOVOT, Israel, Dec. 22, 2015 (GLOBE NEWSWIRE) -- Evogene Ltd. (NYSE:EVGN) (TASE:EVGN), a leading company for the improvement of crop productivity and economics for the food, feed and fuel industries, today announced the appointment of Eyal Leibovitz as Chief Financial Officer.
Read more →EVGNEvogene Officially Opens Research and Development Facility in St. Louis, Missouri
REHOVOT, Israel, Nov. 19, 2015 (GLOBE NEWSWIRE) -- Evogene Ltd. (NYSE:EVGN) (TASE:EVGN), a leading company for the improvement of crop productivity and economics for the food and feed industries, will officially open its new Research and Development facility in St. Louis today wi
Read more →EVGNEvogene to Present at LD Micro Invitational
REHOVOT, Israel, May 28, 2015 (GLOBE NEWSWIRE) -- Evogene Ltd. (NYSE:EVGN) (TASE:EVGN), a leading company for the improvement of crop productivity and economics for the food, feed and biofuel industries, announced today that Ofer Haviv, Evogene's President and CEO will make a pre
Read more →EVGNEvogene Files Annual Report for the Year Ended December 31, 2014
REHOVOT, Israel, April 30, 2015 (GLOBE NEWSWIRE) -- Evogene Ltd. (NYSE:EVGN) (TASE:EVGN), a leading company for the improvement of crop quality, productivity and economics for the food, feed and biofuel industries, announced today that it has filed its annual report on Form 20-F
Read more →EVGNEvogene's First Quarter 2015 Earnings Announcement Schedule
REHOVOT, Israel, April 28, 2015 (GLOBE NEWSWIRE) -- Evogene Ltd. (NYSE:EVGN) (TASE:EVGN), a leading company for the improvement of crop productivity and economics for the food, feed and biofuel industries, announced today that it will release its financial results for the first q
Read more →EVGNEvogene CEO Ofer Haviv and Marrone Bio Innovations CEO Pam Marrone to Participate in 'Profiling Tomorrow's Ag Solutions' Panel Discussion at AgriVest 2015
REHOVOT, Israel and DAVIS, Calif., April 27, 2015 (GLOBE NEWSWIRE) -- Evogene Ltd. (NYSE:EVGN) (TASE:EVGN), a leading company for the improvement of crop productivity and economics for the food, feed and biofuel industries, and Marrone Bio Innovations, Inc. (MBI), (Nasdaq:MBII),
Read more →EVGNEvogene Discloses First Collaboration With Leading Multinational Food Company for Improving Crop Productivity
REHOVOT, Israel, March 18, 2015 (GLOBE NEWSWIRE) -- Evogene Ltd. (NYSE:EVGN) (TASE:EVGN), a leading company for the improvement of crop productivity and economics for the food, feed and biofuel industries, disclosed today its first collaboration agreement with a multinational foo
Read more →EVGNEvogene Introduces Biology Driven Ag-Chemical Discovery Platform
REHOVOT, Israel, Feb. 24, 2015 (GLOBE NEWSWIRE) -- Evogene Ltd. (NYSE:EVGN) (TASE:EVGN), a leading company for the improvement of crop productivity and economics for the food, feed and biofuel industries, announced today the introduction of its biology-driven platform for the dis
Read more →EVGNEvogene to Establish Research and Development Facility in the United States
REHOVOT, Israel, Feb. 9, 2015 (GLOBE NEWSWIRE) -- Evogene Ltd. (NYSE:EVGN) (TASE:EVGN), a leading company for the improvement of crop productivity and economics for the food, feed and biofuel industries, today announced it has signed a Letter of Intent with plans to establish a r
Read more →EVGNEvogene's Fourth Quarter and Full Year 2014 Earnings Announcement Schedule
REHOVOT, Israel, Feb. 5, 2015 (GLOBE NEWSWIRE) -- Evogene Ltd. (NYSE:EVGN) (TASE:EVGN), a leading company for the improvement of crop quality, productivity and economics for the food, feed and biofuel industries, announced today that it will release its financial results for the
Read more →EVGNEvogene New Gene Optimization Program Being Incorporated Into Yield & Environmental Stress Collaboration With Monsanto
REHOVOT, Israel, Feb. 4, 2015 (GLOBE NEWSWIRE) -- Evogene Ltd. (NYSE:EVGN) (TASE:EVGN), a leading company for the improvement of crop productivity and economics for the food, feed and biofuel industries, announced today that its recently developed comprehensive gene optimization
Read more →EVGNEvogene Reports Third Quarter 2014 Financial Results
REHOVOT, Israel, Nov. 10, 2014 (GLOBE NEWSWIRE) -- Evogene Ltd. (NYSE:EVGN) (TASE:EVGN), a leading company for the improvement of crop quality, productivity and economics for the food, feed and biofuel industries, announced today its financial results for the quarter and nine mon
Read more →EVGNEvogene Announces Expansion of Crop Protection Activities
REHOVOT, Israel, Oct. 29, 2014 (GLOBE NEWSWIRE) -- Evogene Ltd. (NYSE:EVGN) (TASE:EVGN), a leading company for the improvement of crop productivity and economics for the food, feed and biofuel industries, today announced the expansion of its crop protection activities with the co
Read more →EVGNEvogene's Third Quarter 2014 Earnings Announcement Schedule
REHOVOT, Israel, Oct. 22, 2014 (GLOBE NEWSWIRE) -- Evogene Ltd. (NYSE:EVGN) (TASE:EVGN), a leading company for the improvement of crop quality, productivity and economics for the food, feed and biofuel industries, announced today that it will release its financial results for the
Read more →EVGNEvogene Subsidiary and Embrapa to Cooperate on Advancing Castor Cultivation in Brazil
REHOVOT, Israel and CAMPINA GRANDE, Brazil, Oct. 20, 2014 (GLOBE NEWSWIRE) -- The Brazilian Agricultural Research Corporation (Embrapa), Brazil's leading agricultural research institution, and Evogene Ltd. (NYSE:EVGN) (TASE:EVGN), a leading plant genomics company specializing in
Read more →EVGNEvogene Reports Second Quarter 2014 Financial Results
REHOVOT, Israel, Aug. 20, 2014 (GLOBE NEWSWIRE) -- Evogene Ltd. (NYSE:EVGN) (TASE:EVGN), a leading plant genomics company specializing in enhancing crop productivity for the food, feed and biofuel industries, announced today its financial results for the quarter and six months en
Read more →EVGNEvogene to Present at Credit Suisse 2014 Basic Materials Conference
REHOVOT, Israel, Aug. 19, 2014 (GLOBE NEWSWIRE) -- Evogene Ltd. (NYSE:EVGN) (TASE:EVGN), a leading plant genomics company specializing in enhancing crop productivity for the food, feed and biofuel industries, announced today that Mr. Ofer Haviv, Evogene's President and CEO, will
Read more →EVGNEvogene Reports First Quarter 2009 Financial Results
REHOVOT, Israel, May 19, 2009 (GLOBE NEWSWIRE) -- Evogene Ltd. (TASE:EVGN) announced today its financial results for the first quarter ended March 31, 2009. Ofer Haviv, Evogene's president and CEO stated: "We are very pleased to conclude additional quarter of growth and progress
Read more →EVGNEvogene Reports Fourth Quarter and Annual 2008 Financial Results
REHOVOT, Israel, March 11, 2009 (GLOBE NEWSWIRE) -- Evogene Ltd. (TASE:EVGN) announced today its financial results for the fourth quarter and year ended December 31, 2008. These results include initial activities under the Monsanto Collaboration Agreement and the Monsanto Investm
Read more →EVGNEvogene Reports Third Quarter 2008 Financial Results
REHOVOT, Israel, Nov. 28, 2008 (GLOBE NEWSWIRE) -- Evogene Ltd. (TASE:EVGN) announced today its financial results for the third quarter ended September 30, 2008. Ofer Haviv, Evogene's president and CEO stated: "We are very pleased by our continuing progress and the achievements
Read more →Competitive Position
How EVGN ranks across every disease it competes inCompetitive Position is a premium feature
See how EVGN ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial